Award Number: W81XWH-10-1-0824

TITLE: $^{64}$Cu-DOTA-Trastuzumab PET Imaging in Women with HER2-Overexpressing Breast Cancer

PRINCIPAL INVESTIGATOR: Joanne Mortimer

CONTRACTING ORGANIZATION: City of Hope Beckman Research Institute
Duarte, CA 91010-3000

REPORT DATE: October 2013

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**REPORT DOCUMENTATION PAGE**

<table>
<thead>
<tr>
<th>1. REPORT DATE</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2013</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. REPORT TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. DATES COVERED</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 September 2010 – 30 September 2013</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. TITLE AND SUBTITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>64Cu-DOTA-Trastuzumab PET Imaging in Women with HER2-Overexpressing Breast Cancer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5a. CONTRACT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5b. GRANT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>W81XWH-10-1-0824</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5c. PROGRAM ELEMENT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. AUTHOR(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Mortimer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5d. PROJECT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5e. TASK NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5f. WORK UNIT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>City of Hope Beckman Research Institute</td>
</tr>
<tr>
<td>Duarte, CA 91010-3000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. PERFORMING ORGANIZATION REPORT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Army Medical Research and Materiel Command</td>
</tr>
<tr>
<td>Fort Detrick, Maryland 21702-5012</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10. SPONSOR/MONITOR'S ACRONYM(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12. DISTRIBUTION / AVAILABILITY STATEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved for Public Release; Distribution Unlimited</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13. SUPPLEMENTARY NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objectives. Patients with metastatic breast cancer identified as human epidermal growth factor receptor 2 (HER2)-positive (HER2+) routinely receive the anti-HER2 antibody trastuzumab plus chemotherapy. 64Cu-DOTA-trastuzumab/PET-CT has high tumor detection sensitivity in HER2+ patients [Bading, et al., JNM 2012;53 (Suppl 1):229P]. We are also imaging HER2- patients and present an initial comparison of tumor uptake between the two groups. Methods. Patients with biopsy-proven HER2+ (n=9) or HER2- (n=4) metastatic breast cancer who had not received anti-HER2 therapy for ≥4 mo were given trastuzumab i.v. (45 mg, to reduce liver uptake) prior to i.v. injection of 64Cu-DOTA-trastuzumab (364-512 MBq). PET-CT scans were obtained at 21-25 h (Day 1; 3-4 bed positions, 20 or 15 min each) and 47-49 h (Day 2; 1-2 bed positions, 60 or 30 min each) over fields of view based on recent (5-17 d prior) 18F-FDG scans. Tumor uptake was measured as body weight-normalized SUV [maximum voxel (SUVmax) and whole-tumor (SUVwt)]. Results. For Day 1, mean SUVmax was 77% higher in lesions from HER2+ vs HER2- patients [(n, mean, median, sd, range) = (57, 7.8, 6.6, 4.3, 2.4-22.5) and (25, 4.4, 4.1, 1.1, 3.0-6.8), respectively; p&lt;1x10^-6 by 2-tailed t test on log-transformed data]. Day 2 and SUVwt results were qualitatively the same as Day 1 SUVmax. Using median Day 1 SUVmax for a given lesion site and patient (pt), analysis for the two most common sites showed: bone [HER2+ (6 pts) 91% &gt; HER2- (3 pts), p&lt;0.05] and lymph nodes [HER2+ (8 pts) 54% &gt; HER2- (3 pts), p&lt;0.05]. Conclusions. Tumor uptake of 64Cu-DOTA-trastuzumab was higher on average in HER2+ vs HER2- patients, with significant intra-group and intra-patient variability. Our observations suggest that, by 1 d post-injection, uptake reflects binding of the radiotracer to HER2. Intra-group and intra-patient heterogeneity may have been due to variations in tumor HER2 expression, and/or other factors (blood clearance, blood-tumor transport, etc.) that influence uptake of 64Cu-DOTA-trastuzumab.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15. SUBJECT TERMS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16. SECURITY CLASSIFICATION OF:</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. REPORT U</td>
</tr>
<tr>
<td>b. ABSTRACT U</td>
</tr>
<tr>
<td>c. THIS PAGE U</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. LIMITATION OF ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>UU</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18. NUMBER OF PAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>19a. NAME OF RESPONSIBLE PERSON</th>
</tr>
</thead>
<tbody>
<tr>
<td>USAMRMC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>19b. TELEPHONE NUMBER (include area code)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
# Table of Contents

1. Introduction ................................................................. 3
2. Keywords ................................................................. 4
3. Overall Project Summary .................................................. 4
4. Key Research Accomplishments ......................................... 6
5. Conclusion .................................................................. 6
7. Inventions, Patents and Licenses ......................................... 6
8. Reportable Outcomes ....................................................... 6
9. Other Achievements ....................................................... 7
10. References ................................................................. 7
11. Appendices ................................................................. 7
1. INTRODUCTION:

The term “breast cancer” encompasses a number of different diseases that are clinically defined by hormone receptor status and HER2 expression. HER2 has tyrosine kinase activity that results in intracellular signaling and activation of genes for cell growth and survival. Women whose cancers overexpress the HER2 protein have a distinct natural history and are candidates for treatment with trastuzumab. Trastuzumab is at humanized IgG-1 antibody that binds to the ectodomain of HER2. When combined with chemotherapy, trastuzumab significantly improves the survival of women with both early stage and advanced disease. The pathologic assessment of HER2 status is made on the primary tumor or metastatic foci. Generally this is small sampling of a portion of one tumor and many not reflect the entire tumor or other sites of disease. HER2 overexpression and candidacy for trastuzumab is defined as 3+ staining by immunohistochemistry (IHC) or gene amplification by fluorescence in situ hybridization (FISH). In the randomized trials of HER2-directed therapy, a consistent group of women enrolled were actually HER2 negative on central pathology review. In both the adjuvant and metastatic settings, those who receive HER2 directed therapy did better. This suggests that HER2-directed therapy should be expanded to include some women with HER2 negative breast cancer.

The impact of HER2 directed therapies on disease outcome is considerable. However, the cost, potential risk of cardiac toxicity, and inconvenience of intravenous administration make it imperative that an accurate assessment of HER2 be made in all women with breast cancer. We hypothesize that a functional assessment of HER2 will be more accurate than pathologic assessment.

Positron emission tomography (PET) provides a non-invasive way of studying tumor location, metabolic functions, and response to therapy. In breast cancer, PET imaging is used to stage women with advanced disease and to assess response to chemotherapy and endocrine therapy before tumor regression can be documented on clinical or radiological exam. The ability to identify patients who may benefit from systemic therapy is critically important to the quality of life of patient; toxicities from ineffective therapies are prevented and medical costs are contained.

Radiolabeled trastuzumab has effectively been used to study HER2 positive breast cancers in animal models and in humans, in part because trastuzumab has a high rate of internalization, which results in trapping of radiometals within the cell. 64Cu-DOTA-trastuzumab, first developed at City of Hope, accurately identified HER2 positive breast cancer in nude mice bearing an MCF7 HER2 overexpressing xenografts. Others have been unable to demonstrate the utility of trastuzumab-based PET imaging. Because normal tissues that express HER2 will bind the radiolabeled (hot) antibody, administration of a “cold dose” of antibody might improve the tumor specificity of the radiographic image. None of the studies that have utilized radiolabeled trastuzumab as an imaging agent have consistently administered a large “cold dose” of trastuzumab prior to radiographic imaging. We hypothesize that the dose of “cold antibody” is critical for image quality. We believe that too high a dose of “cold antibody” will reduce tumor uptake and thereby compromise the quality of the radiographic image.

The primary objective of this pilot study is to determine the optimal dose of cold antibody required for 64Cu-DOTA-trastuzumab PET to produce a high image quality in women with metastatic HER2 positive breast cancer. In addition, we will assess the impact of the
cold antibody dose on cardiac uptake of $^{64}$Cu-DOTA-trastuzumab. To establish the optimal dose of cold antibody, we will image women with documented metastatic breast cancer with 3 different protein (trastuzumab) doses - 5 mg, 50 mg, and 4 mg/kg.

Once we have established the optimal dose of “cold antibody” the secondary objective was to correlate tumor uptake of $^{64}$Cu-DOTA-trastuzumab PET with the degree of immunopositivity of HER2 in women with metastatic disease. Women with metastatic breast cancer that is 1+, 2+, or 3+ positive by IHC assessment of HER2 will undergo a $^{64}$Cu-DOTA-trastuzumab PET imaging. We will correlate the standardized uptake values (SUVs) of tumor identified on $^{64}$Cu-DOTA-trastuzumab PET with the degree of positivity of HER2 by FISH.

We believe that functional imaging with $^{64}$Cu-DOTA-trastuzumab PET has the potential to improve the accuracy of HER2 assessment in vivo. Future studies will address tumor biomarker assessment with serial $^{64}$Cu-DOTA-trastuzumab PET and $[^{18}\text{F}]$FDG/PET before and after treatment with trastuzumab to determine which patients are likely to benefit from the drug.

2. KEYWORDS: Provide a brief list of keywords (limit to 20 words).

$^{64}$Cu-DOTA-trastuzumab PET
Functional imaging
HER2 positive

3. OVERALL PROJECT SUMMARY:

Aim 1: Determine the dose of pre-administered cold antibody that optimizes image quality of $^{64}$Cu-DOTA-trastuzumab PET without increasing the radiation dose to the heart in women with metastatic HER2 positive breast cancer.

Study 1: Eight women underwent $^{64}$Cu-DOTA-trastuzumab PET and $^{18}$F-FDG/PET before and after treatment with trastuzumab. Initially we planned to image 15 women who would receive 3 different pre-administered doses of trastuzumab. The two women who received the lowest dose (5 mg) had poor image quality compared to those receiving 50 mg. Communications with investigators who preadministered larger doses (4 mg/kg) also had poor image quality. We anticipated that the higher dose may have resulted in binding to the tumor receptors precluded uptake of the radiolabel. Therefore we discontinued this study with 8 patients accrued.

Findings as a result of Study 1:
1.) $^{64}$Cu-DOTA-trastuzumab PET is feasible
2.) We identified no significant cardiac uptake on $^{64}$Cu-DOTA-trastuzumab PET
3.) We found a high degree of concordance between $^{18}$F-FDG PET and $^{64}$Cu-DOTA-trastuzumab PET.
4.) A preadministered dose of 45 mg cold trastuzumab resulted in a 75% decrease in uptake of $^{64}$Cu and improved image quality. This became the standard for subsequent $^{64}$Cu-DOTA-trastuzumab PET imaging.

Aim 2: Determine whether tumor uptake on $^{64}$Cu-DOTA-trastuzumab PET correlates with tumor expression of HER2 in women with metastatic disease.

Study 2: Ten women whose HER2 status was 1+,2+, or 3+ underwent $^{64}$Cu-DOTA-trastuzumab PET and $^{18}$F-FDG/PET before and after treatment with trastuzumab. We
Findings as a result of Study 2:
1.) $^{64}$Cu-DOTA-trastuzumab PET uptake was observed in patients whose tumors were considered by pathologic assessment to be HER2 negative.

Figure 1: $^{64}$Cu-DOTA-trastuzumab uptake in HER2 negative patients. Arrows indicate $^{64}$Cu-positive lesions in (A) the left breast and right axilla of a patient with HER2 2+/FISH- disease, and (B) the right mastectomy bed of a patient with HER2 1+ disease.

2.) $^{64}$Cu-DOTA-trastuzumab PET uptake was directly related to the degree of HER2 positivity by IHC assessment. (Figure 2)
4. KEY RESEARCH ACCOMPLISHMENTS:
   In this research grant we were able to demonstrate that:
   a. $^{64}$Cu-DOTA trastuzumab PET/CT imaging is feasible.
   b. The pre-administration of trastuzumab 50 mg resulted in a 75% decrease in hepatic uptake of $^{64}$Cu and resulted in improved image quality.
   c. In women with metastatic HER2 positive breast cancer $^{64}$Cu-DOTA trastuzumab PET/CT imaging was comparable to FDG-PET/CT in the identification of metastatic disease.
   d. In women with metastatic HER2 negative breast cancers, the uptake of $^{64}$Cu-DOTA trastuzumab on PET/CT was less intense than for women with HER2 positive disease.

5. CONCLUSION: We were able to demonstrate the feasibility of using $^{64}$Cu labeled trastuzumab for PET imaging. We were able to improve the quality of the PET images by pre-administering 45 mg of trastuzumab. Even HER2 negative breast cancers demonstrate uptake of $^{64}$Cu-DOTA-trastuzumab PET.

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:
   a. Our first manuscript entitled “” is In Press in the Journal of Nuclear Medicine and will be published in the January 2014 issue. The second manuscript is in preparation.
   b. The data were presented at the following meetings as poster presentations:
      a. ASCO May 2012 and 2013
      b. San Antonio Breast Cancer Symposium 2012 and 2013
      d. Radiologic Society of North America 2012
   c. Data were presented at two institutional Cancer Center Retreats for the Phase I Research meeting 2013.

7. INVENTIONS, PATENTS AND LICENSES: NA

8. REPORTABLE OUTCOMES:
   Other investigators have tested the use of either Indium-111 of Copper-64 labeled trastuzumab. Prior clinical studies have generally included patients who were already on treatment with trastuzumab and the determination of HER2 status was based on the status of the primary cancer. Participants in our trial underwent biopsy of a metastatic focus prior to imaging and patients could not have received a HER2-directed therapy for more than 60 days. Therefore, we have knowledge of the HER2 status immediately prior to imaging and the co-administration of therapeutic trastuzumab did not confound our results. We were able to demonstrate that a small dose of pre-administered trastuzumab improved the image quality. We also demonstrated that the uptake of $^{64}$Cu-DOTA-trastuzumab on PET imaging correlated with the intensity of HER2 staining by immunohistochemistry. $^{64}$Cu-DOTA-trastuzumab PET uptake was observed in women whose cancers were considered HER2 negative by current pathologic criteria. Given this interesting observation, we hypothesize that $^{64}$Cu-DOTA-trastuzumab PET uptake may help to identify women who might benefit from the therapeutic immunoconjugate, T-DM1, including women with HER2 negative breast cancers.
9. **OTHER ACHIEVEMENTS:** Nothing to report.

10. **REFERENCES:**


11. **APPENDICES**
Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET

Joanne E. Mortimer1, James R. Bading2, David M. Colcher2, Peter S. Conti3, Paul H. Frankel4, Mary I. Carroll1, Shan Tong2, Erasmus Poku2, Joshua K. Miles2, John E. Shively5, and Andrew A. Raubitschek2

1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California; 2Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; 3Molecular Imaging Center, Department of Radiology, University of Southern California, Los Angeles, California; 4Department of Information Sciences, City of Hope, Duarte, California; and 5Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, California

Women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab. Assessment of HER2 status in recurrent disease is usually made by core needle biopsy of a single lesion, which may not represent the larger tumor mass or other sites of disease. Our long-range goal is to develop PET of radiolabeled trastuzumab for systemically assessing tumor HER2 expression and identifying appropriate use of anti-HER2 therapies. The purpose of this study was to evaluate PET/CT of 64Cu-DOTA-trastuzumab for detecting and measuring tumor uptake of trastuzumab in patients with HER2-positive metastatic breast cancer. **Methods:** Eight women with biopsy-confirmed HER2-positive metastatic breast cancer and no anti-HER2 therapy for 4 mo or longer underwent complete staging, including 18F-FDG/PET/CT. For 6 of the 8 patients, 64Cu-DOTA-trastuzumab injection (364–512 MBq, 5 mg of trastuzumab) was preceded by trastuzumab infusion (45 mg). PET/CT (PET scan duration 1 h) was performed 21–25 (day 1) and 47–49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Scan fields of view were chosen on the basis of 18F-FDG/PET/CT. Tumor detection sensitivity and uptake analysis were limited to lesions identifiable on CT; lesions visualized relative to adjacent tissue on PET were considered PET-positive. Radiolabel uptake in prominent lesions was measured as maximum single-voxel standardized uptake value (SUVmax). **Results:** Liver uptake of 64Cu was reduced approximately 75% with the 45-mg trastuzumab predose, without significant effect on tumor uptake. The study included 89 CT-positive lesions; detection sensitivity was 77%, 89%, and 93% for day 1, day 2, and 18F-FDG, respectively. On average, tumor uptake was similar for 64Cu-DOTA-trastuzumab and 18F-FDG (mean SUVmax and range were 8.1 and 3.0–22.5, respectively, for day 1 [n = 48]; 8.9 and 0.9–28.9, respectively, for day 2 [n = 38]; and 9.7 and 3.3–25.4, respectively, for 18F-FDG [n = 56]), but same-lesion SUVmax was not correlated between the 2 radiotracers. No toxicities were observed, and estimated radiation dose from 64Cu-DOTA-trastuzumab was similar to 18F-FDG. **Conclusion:** 64Cu-DOTA-trastuzumab visualizes HER2-positive metastatic breast cancer with high sensitivity and is effective in surveying disseminated disease. A 45-mg trastuzumab predose provides a 64Cu-DOTA-trastuzumab biodistribution favorable for tumor imaging. 64Cu-DOTA-trastuzumab PET/CT warrants further evaluation for assessing tumor HER2 expression and individualizing treatments that include trastuzumab.

Key Words: 64Cu-labeled trastuzumab; HER2; breast cancer


DOI: 10.2967/jnumed.113.122630

Overexpression of human epidermal growth factor receptor 2 (HER2) is identified in 20% of breast cancers (1). Women with HER2-positive breast cancer are candidates for treatment with the humanized anti-HER2 antibody trastuzumab. When combined with chemotherapy, trastuzumab increases overall survival for all stages of HER2-positive breast cancer.

Trastuzumab is used in newly diagnosed HER2-positive breast cancer as adjuvant or neoadjuvant therapy and as treatment for metastatic disease at presentation or relapse if more than 6 mo since adjuvant trastuzumab. Response rates are at best about 25% and 50%, respectively, for first-line trastuzumab and trastuzumab plus chemotherapy (2). Furthermore, in the adjuvant setting, patients classified as HER2-negative sometimes benefit (3). There is a clear need to better identify those patients who may benefit from these costly and potentially toxic therapies.

The accurate and comprehensive assessment of tumor HER2 status is critical in determining treatment. However, the pathologic assessment of HER2 status suffers from interlaboratory discordance and lack of a clear definition of positivity (4). Furthermore, confirmation of recurrent disease is usually made by core needle biopsy of an accessible lesion and may not represent the larger tumor mass or other sites of disease. Differences in HER2 expression between primary and metastatic tumors have been observed in as many as 20% of patients, especially when metastasis occurs after adjuvant or neoadjuvant therapy (5–7).

We hypothesized that assessment of tumor HER2 status can be improved by supplementing pathologic evaluation with functional imaging of HER2. Radiolabeled trastuzumab has been used to image patients with HER2-positive breast cancer, initially with 111In and single-photon imaging (8,9) and more recently with 89Zr and PET (10). Although labeling with the positron-emitting isotope 111In is also a possibility, radiometals are preferred given the known cellular internalization of trastuzumab and subsequent rapid efflux of radiolabel from cells when trastuzumab is labeled with
isotopes of iodine (11). Tumor visualization has been variable, perhaps because the women were on active trastuzumab treatment, which may have inhibited radiolabeled trastuzumab binding to HER2.

The positron-emitting isotope $^{64}$Cu is regularly available from Washington University, St. Louis, and we have extensive experience labeling antibodies with radiometals via the chelating agent DOTA (12). Although its half-life (12.8 h) is short relative to the blood clearance of trastuzumab, $^{64}$Cu has potential advantages over $^{89}$Zr in terms of radiation safety and patient radiation dose. The critical issue, addressed in this study, is whether tumor uptake of $^{64}$Cu-DOTA-trastuzumab is sufficiently rapid to support tumor imaging and quantification within the 48-h time window afforded by $^{64}$Cu. On the basis of our previous clinical study with $^{111}$In-MxDTPA-trastuzumab (9) and promising results in athymic mice bearing HER2-expressing human breast adenocarcinoma xenografts (13), we have obtained an investigational new drug (IND) application for $^{64}$Cu-DOTA-trastuzumab. The primary objective of this pilot study was to evaluate the feasibility and potential utility of CT-supplemented PET scanning of $^{64}$Cu-DOTA-trastuzumab ($^{64}$Cu-DOTA-trastuzumab PET/CT) for lesion detection and uptake measurement in HER2-positive metastatic breast cancer. Similar to other antibodies (14), liver uptake of intravenously administered trastuzumab is strongly dependent on antibody protein load. Thus, we sought to identify a trastuzumab dose that minimizes liver uptake of $^{64}$Cu-DOTA-trastuzumab. Additional goals were to compare $^{64}$Cu-DOTA-trastuzumab with the standard PET radiotracer, $^{18}$F-FDG, and to confirm the safety of the $^{64}$Cu-DOTA-trastuzumab PET/CT procedure.

MATERIALS AND METHODS

Patient Selection

Women with metastatic HER2-positive breast cancer who had not received HER2-directed therapy for 4 mo or more were considered for study participation after undergoing a staging workup that included echocardiogram, bone scanning, and whole-body $^{18}$F-FDG/PET/CT. All candidates underwent biopsy of a metastatic lesion within 28 d before the $^{64}$Cu-DOTA-trastuzumab procedure to confirm recurrent, HER2-positive disease by immunohistochemical staining or fluorescence in situ hybridization. Assessable disease outside the primary breast site, ipsilateral axillary region, and biopsy site was also required. The study protocol was approved by the City of Hope Institutional Review Board and Radiation Safety Committee, and an IND was accepted by the Food and Drug Administration. All patients signed a written informed consent.

$^{64}$Cu-DOTA-Trastuzumab Preparation

Trastuzumab is a recombinant humanized antibody that binds with high affinity to the extracellular domain of the HER2 protein. Radiolabeled trastuzumab was prepared according to procedures defined in IND #10997. The antibody (Herceptin, purchased from Genentech) was conjugated with the active ester of DOTA (Macrocyclics) under current good manufacturing–compliant conditions. $^{64}$Cu (half-life, 12.8 h; 0.18 positrons/decay) was provided by the Mallinckrodt Institute of Radiology, Washington University School of Medicine. DOTA-conjugated antibody was incubated with $^{64}$Cu for 45 min at 43°C, chased with 1 mM diethylenetriamine pentaacetic acid (DTPA), and purified on a size-exclusion, preparative column (Superdex-200). Radiolabeling efficiency was more than 93%. Appropriate fractions were pooled, filtered, and formulated with 1% human serum albumin for patient administration. The $^{64}$Cu-DOTA-trastuzumab preparations were sterile, with endotoxin levels less than 0.05 EU/mL, and immunoreactivity greater than 86%. The DOTA-trastuzumab protein dose per $^{64}$Cu-DOTA-trastuzumab injection was approximately 5 mg.

Administration of Trastuzumab and $^{64}$Cu-DOTA-Trastuzumab

Patients were closely monitored for acute adverse reactions during trastuzumab administrations. $^{64}$Cu-DOTA-trastuzumab (364–512 MBq; mean, 450 MBq) was infused intravenously in 25 mL of saline over 10 min. Dijkers et al. found that, compared with 10 mg, 50 mg of trastuzumab substantially reduced blood clearance and liver uptake of $^{89}$Zr-trastuzumab in trastuzumab-naïve patients (10). To match the trastuzumab dose found effective in that study, patients receiving non-radiolabeled trastuzumab were infused intravenously with the antibody (45 mg in 50 mL of saline given over 15 min) immediately before radioactive injection.

The first 4 patients in our study were randomly assigned to receive trastuzumab doses of 5 or 50 mg. When $^{64}$Cu-DOTA-trastuzumab PET/CT of those patients confirmed the findings of Dijkers et al., we adopted the 50-mg dose for the remainder of the study.

PET/CT Imaging

Imaging was performed with a Discovery Ste 16 PET/CT scanner (GE Healthcare) operated in 3-dimensional mode (septa retracted). The PET axial field of view is 15.4 cm (image slice thickness, 3.3 mm). PET images were reconstructed using an iterative, ordered-subsets expectation maximization algorithm with gaussian postsmoothing and standard corrections for nonuniform detector sensitivity, scanner dead time, random, and scattered coincidence events. Correction for photon attenuation was based on coregistered CT scans acquired during the same examination. The measured spatial resolution of the PET images was approximately 9 mm in full width at half maximum.

Patients underwent a standard $^{18}$F-FDG/PET/CT examination 13 d or fewer before the $^{64}$Cu-DOTA-trastuzumab procedure. Patients fasted 6 h or more before injection of $^{18}$F-FDG. Serum glucose concentration measured at time of examination was high (184 mg/dL) for one patient and normal ($<120$ mg/dL) for the others. Injected $^{64}$Cu activity was limited to 555 MBq (15 mCi), based on radiation dose estimates calculated from the pharmacokinetics of $^{111}$In-MxDTPA-trastuzumab (9). One hour was chosen as a reasonable limit for PET scan duration. Within those constraints, disease location as judged from the preceding $^{18}$F-FDG PET/CT examination was used in choosing the axial coverage for the $^{64}$Cu-DOTA-trastuzumab PET/CT scans. The first (day 1) $^{64}$Cu scan was performed 21–25 h after injection to allow radiolabeled antibody accumulation in tumor. A second (day 2) scan was obtained 47–49 h after injection. Day 1 scans comprised of 3 or 4 (39 or 51 cm axial extent, 20 or 15 min per bed position) and day 2 scans comprised of 1 or 2 (15 or 27 cm axial extent, 60 or 30 min per bed position) contiguous bed positions, respectively, depending on patient body thickness. Signal-to-noise characteristics of the $^{64}$Cu-DOTA-trastuzumab images approximated those of the $^{18}$F-FDG scans (Fig. 1).

Image Analysis

PET/CT examinations were interpreted by a nuclear medicine boarded radiologist. Tumor detection sensitivity and uptake analysis were limited to lesions identifiable on CT; lesions visualized relative to adjacent tissue on PET were considered PET-positive. PET-positive lesions were disregarded if CT was judged inconclusive. PET-positive findings with $^{64}$Cu-DOTA-trastuzumab but not $^{18}$F-FDG, and having no correlated CT lesion, were scored as false-positives. Because of possible $^{18}$F-FDG or nonspecific antibody uptake secondary to biopsy, biopsied tumor sites were not included in the analysis. A detailed description of the lesion detection analysis is given in the supplemental material (available only online at http://jnm.snmjournals.org).

Radiolabel uptake in as many as 10 of the most prominent lesions per patient, as well as selected nontumor tissues and organs, was measured in terms of standardized uptake value (SUV = tissue activity
Human Anti-Trastuzumab Antibody Response

Serum samples obtained just before trastuzumab/64Cu-DOTA-trastuzumab infusion and 1, 3, and 6 mo later, when possible, were evaluated for immune responses using a size-exclusion high-performance liquid chromatography shift assay. Samples (125 μL) were incubated with radiolabeled DOTA-trastuzumab (111In, 9 μCi/μg, 0.1 μCi) and then run on a Superose-6 size-exclusion column at 0.4 mL/min in phosphate-buffered saline/0.05% NaN3. A change in the elution pattern of the radiolabeled trastuzumab consistent with higher molecular weight was considered positive for an antiantibody response.

Statistical Analysis

Statistical analysis was performed using R software (version 2.12.1, The R Foundation of Statistical Computing). Lesion detection sensitivities were compared by a 2-sided Fisher exact test. Comparison of tumor uptake between trastuzumab doses and among lesion sites used ANOVA to evaluate both dose/lesion site and patient effects, with Holm’s method to adjust for multiple comparisons. Linear regression analysis was used to demonstrate correlation between whole-tumor SUV and SUV_max and lack of correlation between 18F-FDG and 64Cu-DOTA-trastuzumab. The effect of trastuzumab dose on organ uptake was evaluated by Wilcoxon rank-sum test. P values of less than 0.05 were considered statistically significant.

RESULTS

Patient Characteristics

Eight of 10 women considered for study participation met the eligibility criteria. Biopsies of 2 patients previously treated for early stage HER2-positive breast cancer showed recurrent disease to be HER2-negative. Participating patients are characterized in Table 1.

Lesion Detection Sensitivity of 64Cu-DOTA-Trastuzumab PET/CT

Figure 1 illustrates 64Cu-DOTA-trastuzumab image quality and tumor visualization, compared with 18F-FDG. Tumor-to-nontumor contrast for 64Cu-DOTA-trastuzumab was generally high (Fig. 1, A).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Trastuzumab protein dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>5</td>
</tr>
<tr>
<td>Age (y)</td>
<td>6</td>
</tr>
<tr>
<td>Prior anti-HER2 therapy</td>
<td>8</td>
</tr>
<tr>
<td>Hormone receptor and HER2 status of recurrent disease</td>
<td>5</td>
</tr>
<tr>
<td>ER PR positive</td>
<td>1</td>
</tr>
<tr>
<td>ER PR negative</td>
<td>3</td>
</tr>
<tr>
<td>HER2</td>
<td>4</td>
</tr>
<tr>
<td>IHC3+</td>
<td>7</td>
</tr>
<tr>
<td>IHC2+/FISH positive</td>
<td>1</td>
</tr>
<tr>
<td>Sites of metastatic disease</td>
<td>1</td>
</tr>
</tbody>
</table>

TABLE 1 Patient Demographics and Clinical Characteristics

*Months since last anti-HER2 therapy administration
ER = estrogen receptor; PR = progesterone receptor; IHC = immunohistochemistry; FISH = fluorescence in situ hybridization.

64Cu-TRASTUZUMAB PET IN HER2+ BREAST CANCER • Mortimer et al.
patient A). Exceptions occurred for lymph nodes in the cervical, clavicular, and mediastinal regions due to high blood-pool activity (Fig. 1, patient B) and in the liver for the 5-mg trastuzumab dose (Fig. 1, patient A). Visualization of lymph nodes in regions of high blood activity improved between day 1 and day 2 but changed little for other lesion sites between the 2 scans (Fig. 2).

Lesion detection statistics are summarized in Table 2. Overall detection sensitivity with 18F-FDG PET/CT (93%) was consistent with general experience in metastatic breast cancer (16). All 8 patients had CT-positive lesions that were detected with 64Cu-DOTA-trastuzumab PET. There were no statistically significant differences in 64Cu lesion detection sensitivity between 5- and 50-mg trastuzumab doses (data not shown). On day 1, 64Cu detection sensitivity was lower for lymph nodes than for bone lesions. Overall, detection sensitivity for 64Cu-DOTA-trastuzumab on day 1 was lower than for 18F-FDG, with the difference being due primarily to the low sensitivity of lymph nodes in regions of high blood activity. There were 7 instances in which a CT-positive lesion was detected with 18F-FDG but not 64Cu-DOTA-trastuzumab on either day 1 or day 2. In 6 instances (3 bone, 2 liver, and 1 node), a CT-positive lesion was detected with 64Cu-DOTA-trastuzumab but not with 18F-FDG. 18F FDG false-negative bone and liver lesions are illustrated in Figures 2 and 3B, respectively.

There was only 1 instance of a false-positive 64Cu-DOTA-trastuzumab lesion, which occurred in the colon and may have been associated with diverticulitis. In 1 patient with numerous bone metastases, 64Cu-DOTA-trastuzumab, or both 64Cu-DOTA-trastuzumab and 18F-FDG, produced hot spots in rib regions too small to be assessed on associated CT (Fig. 1, patient A).

Effects of Trastuzumab Protein Dose

Blood clearance was slowed, and liver uptake of 64Cu-DOTA-trastuzumab was markedly depressed in patients preinfused with trastuzumab (45 mg) (supplemental material, Fig. 1). However, with only 2 patients at the lower protein dose, SUV differences between the 50- and 5-mg trastuzumab doses were not statistically significant ($P = 0.10$ and 0.05 on days 1 and 2 for blood; $P = 0.10$ and 0.07 on days 1 and 2 for liver). Trastuzumab predosing dramatically improved visualization of hepatic metastases (Fig. 3) and had little effect on 64Cu-DOTA-trastuzumab uptake in heart wall (supplemental material, Fig. 1), kidney, or spleen (data not shown).

No statistically significant difference in tumor uptake of 64Cu-DOTA-trastuzumab was observed between the 2 trastuzumab doses. Tumor SUV$_{max}$ was generally higher for the 5- than for the 50-mg dose on day 1 (mean ± SD, 11.3 ± 5.9, compared with 6.7 ± 2.4, $P = 0.01$) but trended in the other direction on day 2 (mean ± SD, 5.9 ± 3.7, compared with 9.6 ± 5.9, $P = 0.11$). When ANOVA included both a patient effect (i.e., accounted for varying numbers of lesions among different patients) and a dose effect, there was no significant trastuzumab dose effect on either day.

Heterogeneity of 64Cu-DOTA-Trastuzumab Uptake in Tumors

Uptake varied widely both among and within patients (Fig. 4). For the data included in Figure 4, mean SUV$_{max}$ ranged from 5.5 to 15.0 g/mL among the 8 patients. Within patients, SUV$_{max}$ varied between 2- and 5-fold in 7 patients and 22-fold in 1 patient.

The variability was, in part, associated with lesion site (Fig. 5).

Tumor Uptake Compared Between 64Cu-DOTA-Trastuzumab and 18F-FDG

Uptake of 64Cu-DOTA-trastuzumab and 18F-FDG was comparable when averaged over all lesions. For combined 5- and 50-mg trastuzumab doses, SUV$_{max}$ mean, median, and range results were 9.7, 9.3, and 3.3–25.4, respectively, for 18F-FDG ($n = 56$); 8.1, 7.0, and 3.0–22.5, respectively, for 64Cu-DOTA-trastuzumab day 1 ($n = 48$); and 9.0, 7.5, and 0.9–28.9, respectively, for 64Cu-DOTA-trastuzumab day 2 ($n = 38$).

ANOVA including both lesion site and patient effects indicated significant lesion site effects for both 64Cu-DOTA-trastuzumab and 18F-FDG (Fig. 5). Pairwise comparisons between sites showed 18F-FDG uptake in liver metastases to be less than in bone metastases ($P < 0.01$), whereas 64Cu-DOTA-trastuzumab uptake on day 2 was higher in liver metastases than in bone metastases ($P < 0.02$).

Same-lesion SUV$_{max}$ for 64Cu-DOTA-trastuzumab and 18F-FDG was uncorrelated ($P = 0.4$; correlation coefficients were $-0.1$). SUV$_{max}$ ratios ($64$Cu-dota-trastuzumab to 18F-fdg) varied from 0.2 to 4.3 (supplemental material, Fig. 2).

Patient Safety

Trastuzumab infusion and 64Cu-DOTA-trastuzumab PET/CT were well tolerated, with no unanticipated toxicity or adverse side effects observed. Antitrastuzumab antibody response assays were negative for 6 patients. Minor increases in higher-molecular-weight...
Comparison with our 111In-MxDTPA-trastuzumab study (4 lesions visualized in 3 of 7 patients with known lesions). A second major objective was to establish a trastuzumab protein load that minimizes liver uptake without inhibiting tumor uptake of 64Cu-DOTA-trastuzumab. We observed that adding 45 mg of trastuzumab to the 5 mg of DOTA-trastuzumab delivered with the radioactive injection approximately doubled blood SUV and reduced liver uptake by 75%–80% on days 1 and 2 after radiotracer injection (supplemental material, Fig. 1). These observations are quantitatively similar to those reported by Dijkers et al. for 89Zr-trastuzumab given with trastuzumab loads of 10 and 50 mg (10).

Comparison with our 111In-MxDTPA-trastuzumab study (trastuzumab load 4–8 mg/kg) suggests that increasing beyond 50 mg of trastuzumab dose would not yield further improvement in the pharmacokinetics or biodistribution of 64Cu-DOTA-trastuzumab. We observed no statistically significant difference in tumor uptake between 5- and 50-mg doses in this small study. However, other investigations have demonstrated that a significant fraction of tumor binding sites can be occupied at antibody loading doses << 4–8 mg/kg (17). Furthermore, the dissociation constant for 111In-DTPA-trastuzumab-HER2 binding is approximately 10 nM (18), a concentration that very likely would be exceeded in tumors at a trastuzumab load of 4–8 mg/kg. This suggests that HER2 saturation may have contributed to the relatively low tumor detection sensitivity in our 111In-MxDTPA-trastuzumab study (4 lesions visualized in 3 of 7 patients with known lesions).

**TABLE 2**

Detection of CT-Positive Lesions with PET

<table>
<thead>
<tr>
<th>Lesion site</th>
<th>18F-FDG*</th>
<th>64Cu-DOTA-trastuzumab†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
<td>Day 2</td>
</tr>
<tr>
<td>All</td>
<td>83 of 89 (93%)</td>
<td>61 of 79 (77%)†</td>
</tr>
<tr>
<td>Bone</td>
<td>35 of 38 (92%)</td>
<td>33 of 36 (92%)</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>30 of 31 (97%)</td>
<td>20 of 31 (65%‡ §)</td>
</tr>
<tr>
<td>Liver</td>
<td>8 of 10 (80%)</td>
<td>1 of 3 (33%)</td>
</tr>
<tr>
<td>Lung</td>
<td>5 of 5 (100%)</td>
<td>4 of 4 (100%)</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>2 of 2 (100%)</td>
<td>0 of 2 (0%)</td>
</tr>
<tr>
<td>Breast</td>
<td>3 of 3 (100%)</td>
<td>3 of 3 (100%)</td>
</tr>
</tbody>
</table>

*Lesions evaluated for 18F-FDG were all included in and evaluated for either of or both 64Cu-DOTA-trastuzumab day 1 and day 2 scans.
†Combined data for 5- and 50-mg trastuzumab doses.
‡P < 0.01 relative to 18F-FDG, all sites.
§P < 0.01 relative to 18F-FDG, lymph nodes.
†P < 0.05 relative to 64Cu-DOTA-trastuzumab day 1, bone.

**DISCUSSION**

Tumor HER2 status and trastuzumab exposure history were more clearly prescribed in the current investigation than in prior imaging studies with trastuzumab (8–10). All patients had biopsy confirmation of HER2 positivity at time of study, and none had received anti-HER2 therapy for at least 4 mo before imaging.

We have clearly shown that, despite the relatively short half-life of the radiolabel, 64Cu-DOTA-trastuzumab PET/CT can effectively detect and quantify tumor uptake in patients with known HER2-positive disease. Other than brain, all anatomic sites common to metastatic breast cancer were included in the patient cohort. Lesions were visualized in all 8 patients examined and were seen in bone, lymph nodes, liver, lung, pleural effusions, and breast. Detection sensitivity was 77% on day 1 and 89% on day 2 (Table 2). Tumor uptake was substantial by 24 h and, on average, increased modestly between 24 and 48 h. Detection of lymph nodes in the neck, upper thorax, and mediastinum is difficult at 24 h because of high blood background but improves by 48 h (Fig. 2). The chief limitation of 64Cu-DOTA-trastuzumab PET/CT is that, because of the 13-h half-life of 64Cu, it does not provide whole-body coverage with acceptable signal-to-noise ratio and scan duration. Nonetheless, as demonstrated here, 64Cu-DOTA-trastuzumab PET can be used effectively in disseminated, HER2-positive breast cancer when disease location is defined in advance by 18F-FDG/PET or CT.

A second major objective was to establish a trastuzumab protein load that minimizes liver uptake without inhibiting tumor uptake of 64Cu-DOTA-trastuzumab. We observed that adding 45 mg of trastuzumab to the 5 mg of DOTA-trastuzumab delivered with the radioactive injection approximately doubled blood SUV and reduced liver uptake by 75%–80% on days 1 and 2 after radiotracer injection (supplemental material, Fig. 1). These observations are quantitatively similar to those reported by Dijkers et al. for 89Zr-trastuzumab given with trastuzumab loads of 10 and 50 mg (10).

Comparison with our 111In-MxDTPA-trastuzumab study (trastuzumab load 4–8 mg/kg) suggests that increasing beyond 50 mg of trastuzumab dose would not yield further improvement in the pharmacokinetics or biodistribution of 64Cu-DOTA-trastuzumab. We observed no statistically significant difference in tumor uptake between 5- and 50-mg doses in this small study. However, other investigations have demonstrated that a significant fraction of tumor binding sites can be occupied at antibody loading doses << 4–8 mg/kg (17). Furthermore, the dissociation constant for 111In-DTPA-trastuzumab-HER2 binding is approximately 10 nM (18), a concentration that very likely would be exceeded in tumors at a trastuzumab load of 4–8 mg/kg. This suggests that HER2 saturation may have contributed to the relatively low tumor detection sensitivity in our 111In-MxDTPA-trastuzumab study (4 lesions visualized in 3 of 7 patients with known lesions).
Heterogeneity of tumor HER2 expression within and among patients is poorly understood (5–7) and may be elucidated by imaging studies with radiolabeled trastuzumab. The high degree of tumor positivity observed in the current study suggests that most lesions in HER2-positive patients have HER2 expression adequate to render them detectable with 64Cu-DOTA-trastuzumab PET/CT. On the other hand, tumor uptake was also highly variable among and within patients (Fig. 4). That heterogeneity suggests a potential role for 64Cu-DOTA-trastuzumab PET/CT in the selection of patients for trastuzumab-based therapy.

Patient selection and scan design for the 64Cu-DOTA-trastuzumab PET examinations relied on prior 18F-FDG scans. Tumor uptake and detection sensitivity were only modestly lower for 64Cu-DOTA-trastuzumab than for 18F-FDG. Most lesions were positively visualized with both radiotracers, and 6 CT-positive tumors were detected with 64Cu-DOTA-trastuzumab and not with 18F-FDG. Same-lesion maximum SUVs for 64Cu-DOTA-trastuzumab and 18F-FDG were uncorrelated, and their ratios (64Cu-DOTA-trastuzumab to 18F-FDG) varied by a factor of 22 (supplemental material, Fig. 2). Tumor uptake of 18F-FDG reflects density of glycolytic activity, which in turn depends on viable cell density and tissue oxygenation status (19–21). In breast cancer, high tumor uptake of 18F-FDG is generally correlated with tumor aggressiveness but not with overexpression of the HER2 oncogene c-erbB-2 (22). For 64Cu-DOTA-trastuzumab, the unproven assumption is that tumor uptake is closely related to HER2 density, which in turn is positively correlated with tumor growth rate and aggressiveness (23). However, the relationship between uptake and HER2 expression may be confounded by factors such as blood clearance and vascular permeability. Because glycolysis and HER2 expression are independently related to tumor aggressiveness, the observed lack of correlation between same-tumor uptake of 64Cu-DOTA-trastuzumab and 18F-FDG suggests that combining the 2 measurements may be useful in predicting patient outcomes.

The procedures used in this study were well tolerated. There were no unexpected toxicities associated with the trastuzumab or 64Cu-DOTA-trastuzumab administrations. Two patients had assay results that might indicate low-level anti-antibody responses after the 64Cu-DOTA-trastuzumab procedure. However, both patients had positive pre-64Cu-DOTA-trastuzumab baseline assays and intermittently positive assays thereafter. This suggests positivity resulted from something other than the 64Cu-DOTA-trastuzumab procedure, such as prior treatment with trastuzumab or the presence of circulating antigen (i.e., HER2 extracellular domain) in the serum, a possibility that we are currently evaluating.

Estimated radiation doses for 64Cu-DOTA-trastuzumab (Table 3) are moderate, compared with 18F-FDG and other imaging procedures with radiolabeled antibodies. For the mean administered activity in this study (450 MBq) and a 50-mg trastuzumab dose, estimated effective dose and maximum organ (heart wall) equivalent dose for 64Cu-DOTA-trastuzumab are 12 and 71 mSv, respectively. 18F-FDG has effective and critical organ (bladder wall) equivalent doses of 11 and 72 mSv, respectively, for the typical

---

**FIGURE 4.** Inter- and intrapatient heterogeneity of 64Cu-DOTA-trastuzumab tumor uptake. Short horizontal lines indicate intrapatient mean SUV<sub>max</sub>. Data are from day 1 (n = 49) or day 2 (n = 7) for lesions not included in day 1 scan. Six of day 2 lesions are for patient 8, for whom data from 2 of 3 scanned bed positions on day 1 were lost due to scanner malfunction. Other day 2 lesion is for patient 6. Patients 6 and 7 received trastuzumab doses of 5 mg; others received 50 mg.

**FIGURE 5.** Tumor uptake of 18F-FDG and 64Cu-DOTA-trastuzumab (day 1 and day 2) vs. lesion site. Short horizontal lines indicate intrasite averages. *<sup>18</sup>F-FDG bone, P < 0.01; †Day 2 bone, P < 0.02.

**TABLE 3**

<table>
<thead>
<tr>
<th>Organ</th>
<th>Equivalent or effective dose per unit injected activity (mSv/MBq)</th>
<th>Equivalent or effective dose per PET examination (mSv)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart wall</td>
<td>0.16</td>
<td>71</td>
</tr>
<tr>
<td>Kidneys</td>
<td>0.09</td>
<td>42</td>
</tr>
<tr>
<td>Liver</td>
<td>0.12</td>
<td>53</td>
</tr>
<tr>
<td>Red marrow</td>
<td>0.04</td>
<td>17</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.10</td>
<td>45</td>
</tr>
<tr>
<td>Whole body</td>
<td>0.02</td>
<td>10</td>
</tr>
<tr>
<td>Effective dose</td>
<td>0.03</td>
<td>12</td>
</tr>
</tbody>
</table>

*Trastuzumab protein dose = 50 mg.
†Calculations used averaged time–activity curves (8 patients) from our 111In-MxDTPA-trastuzumab study (9), which were normalized to averaged blood and organ uptake data from current 64Cu-DOTA-trastuzumab study (8 patients).
‡ Assumes 64Cu injected activity = 450 MBq, average in current study.
injected activity of 555 MBq (15 mCi) (24). Monoclonal antibodies labeled with 111In incur effective and critical organ (spleen and liver) equivalent doses of approximately 40 and 200 mSv, respectively, for the typical injected activity of 185 MBq (5 mCi) (24). Dijkers et al. estimated a radiation dose (presumably effective dose) of 18 mSv from a 37-MBq (1 mCi) injection of 89Zr-trastuzumab (10).

CONCLUSION

We have shown that, in patients with HER2-positive metastatic breast cancer, tumors rapidly accumulate 64Cu-DOTA-trastuzumab to high concentrations, thus supporting both detection and measurement of tumor uptake by 1 d after injection. The rapid uptake, supplemented by prior knowledge of tumor location and extent of disease despite the limited half-life of 64Cu. We have confirmed that 50 mg of trastuzumab protein dose provides a 64Cu-DOTA-trastuzumab biodistribution favorable for tumor imaging. This study demonstrates that 64Cu-DOTA-trastuzumab PET/CT is a practical and acceptably safe procedure in patients with metastatic breast cancer.

We will next broaden the study to include patients with metastatic breast cancer classified as HER2-negative on prescan biopsy and thus correlate tumor uptake of 64Cu-DOTA-trastuzumab with HER2 expression. Beyond that, we envision using 64Cu-DOTA-trastuzumab PET/CT to individualize treatment regimens that include trastuzumab and other HER2 directed therapies.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. This work was supported by the Department of Defense (grant 1024511) and by the National Cancer Institute of the National Institutes of Health under grant number P30CA03572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. No other potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

Jose Reyes, CNMT, obtained the PET/CT scans. Blood samples were assayed for radioactivity and anti-trastuzumab immune response by Nicole Bowles, BA, and Jing Guo, BS, respectively. The production of 64Cu at Washington University School of Medicine is supported by the Department of Energy.

REFERENCES

[AQ1] Please confirm that the correct city has been given for USC/Molecular Imaging Center.

[AQ2] Please confirm that “On average, . . .” retains your meaning with edits.

[AQ3] Please verify the data in any tables and figures, and please confirm that any radiation or radiopharmaceutical doses mentioned in the article are correct.

[AQ4] Can MxDTPA be spelled out?

[AQ5] Please provide a manufacturer for the column.

[AQ6] By “boarded” do you mean “board-certified”?

[AQ7] When solely Curies are given, please also provide Becquerel equivalents.

[AQ8] Please provide a manufacturer for the column.

[AQ9] Correct to add “software” here?

[AQ10] Do you mean “Supplemental Fig. 1” here or the figure 1 from the article? See also elsewhere in the text when “supplemental material, figure...” is referred to.

[AQ11] Ok to add “respectively” here for ““P = 0.10 and 0.05 on days 1 and 2 for blood; P = 0.10 and 0.07 on days 1 and 2 for liver””?

[AQ12] Please confirm that “For combined 5- . . .” retains your meaning.
San Antonio Breast Cancer Symposium 2013

Relationship between $^{64}$Cu-DOTA-trastuzumab positron emission tomography uptake and assessment of HER2 by immunohistochemistry in women with advanced breast cancer. Joanne E. Mortimer, David Colcher, Paul Frankel, Andrew Raubitschek, Mary Carroll, Peter Conti, Shan Tong, Kofi Poku, Joshua Miles, and James Bading.

**Background:** We have utilized $^{64}$Cu-DOTA-trastuzumab with PET imaging to assess the in vivo expression of HER2 in women with advanced breast cancer. We have demonstrated that a preadministered dose of trastuzumab 45 mg prior to injection of $^{64}$Cu-DOTA-trastuzumab resulted in a 75% decrease in the hepatic uptake of Cu-64, resulting in improved image quality.

**Methods:** Patients with biopsy confirmation of recurrent disease located outside the breast and axilla considered for study. Complete staging workup included CT of the chest, abdomen, and pelvis, bone scintigraphy and $^{18}$F FDG PET. At least 1 non-hepatic site of metastasis that was > 2 cm separate from the biopsy site was also required. HER2 status was assessed by both IHC and FISH. Index lesions were identified on CT imaging. After the first two patients, all patients received a cold dose of 45mg of trastuzumab immediately prior to $^{64}$Cu-DOTA-trastuzumab to decrease liver uptake. $^{64}$Cu-DOTA-trastuzumab PET imaging was performed at 24 and 48 hours. Uptake on $^{64}$Cu-DOTA-trastuzumab was correlated with HER2 status by IHC and FISH.

**Results:** Fifteen women have undergone $^{64}$Cu-DOTA-trastuzumab PET imaging and quantitative image analysis. 10 patients were HER2+ (7 IHC 3+, 3 IHC 2+/FISH+), 3 patients were IHC 2+/FISH-, and 2 patients were IHC 1+. Tumor uptake by $^{64}$Cu-DOTA-trastuzumab PET max SUV was higher in HER2+ positive than HER2- patients (1.9-fold higher on day1, p<0.02, and 1.7-fold higher on day2, p<0.05). However, the lowest max SUV was in a HER2+ patient (HER2 2+/FISH+), demonstrating considerable heterogeneity. Conclusion: $^{64}$Cu-DOTA-trastuzumab PET correlates with HER2+ status. However, due to high within and between patient variability, $^{64}$Cu-DOTA-trastuzumab PET imaging could potentially enrich for HER2+ patients that respond to HER2-targeted therapy, and could also suggest some HER2- patients that may benefit from HER2-targeted therapy. This hypothesis needs to be further explored in patients undergoing HER2-targeted therapy. This work was supported by the Department of Defense grant # BC095002.
**Abstract**

Background: We have developed 64Cu-DOTA-Trastuzumab for PET imaging of HER2 positive breast cancer. We have determined that administering trastuzumab (45 mg) prior to 64 Cu-DOTA-trastuzumab sharply reduces the liver uptake of the radiotracer. We are now testing whether tumor uptake of 64 Cu-DOTA-trastuzumab correlates with variable IHC staining in women with advanced breast cancer.

Methods: Eligibility criteria included biopsy confirmation of metastatic breast cancer. The patients received 45 mg of trastuzumab before 64 Cu-DOTA-trastuzumab. PET-CT scans were obtained at 24-72 h (Day 1) and 48-96 h (Day 2) after injection. Lesion was measured in terms of maximum single-voxel SUVmax. Lesions identified on CT and judged to have image intensity > adjacent tissue by an expert radiologist were considered positive on PET.

Results: Forty women (median age 56, range 32-75 years) have undergone imaging. HER2 status was determined by IHC or FISH. In the patients considered HER2 positive by IHC or FISH, 64 Cu-DOTA-trastuzumab uptake was higher in HER2+ than in HER2- patients (SUVmax mean ± SE 4.3 ± 0.8 vs 5.4 ± 0.3, p < 0.001).

Conclusions: 64Cu-DOTA-trastuzumab PET visualizes HER2+ breast cancer. Further studies are needed to establish the clinical utility of this imaging approach.

**Objectives**

1. Determine the dose of pre-administered cold trastuzumab that optimizes tumor image quality of 64Cu-DOTA-trastuzumab PET in women with advanced breast cancer. (Study 1)

2. Determine whether 64Cu-DOTA-trastuzumab PET uptake correlates with HER2 status determined by IHC staining. (Study 2)

**Conclusions**

In eight women with documented HER2 positive metastatic disease:

- The pre-administration of 50 mg trastuzumab resulted in a 75% decrease in hepatic uptake, improving image quality.

40 year old with HER2+ disease. Note 64Cu-DOTA-trastuzumab uptake in skin and axilla

65 year old with HER2+ disease. Note 64Cu-DOTA-trastuzumab uptake in skin and axilla

Inter- and intra-patient heterogeneity of 64Cu-DOTA-trastuzumab tumor uptake. Data are from Day 1 (n = 50), or Day 2 (n = 8) for lesions not included in the Day 1 scan. Seven of the Day 2 lesions are for Patient 14, for whom data from 2 of the 3 scanned bed positions on Day 1 were lost due to scanner malfunction.

All work was performed in accordance with IND # 10997. Project funding was made possible by DOD grant BC095002.
Functional imaging of HER2-positive metastatic breast cancer using
64Cu-DOTA-Trastuzumab Positron Emission Tomography (PET)
Joanne E. Mortimer, Peter Conti, Shan Tong, Jose Reyes, Mary I. Carroll, Kofi Poku, David Colcher, Andrew A. Raubitschek, James R. Bading, Joshua Miles,
1Dept Medical Oncology and Experimental Therapeutics, 2Cancer Immunotherapeutics and Tumor Immunology
City of Hope Cancer Center/Beckman Research Institute, Duarte, CA; USC, Los Angeles, CA 91010

Background

- 25-30% of all breast cancers overexpress the HER2 protein as assessed by IHC or FISH.
- HER2 overexpression is used to guide the use of anti-HER therapy with trastuzumab.
- Following systemic therapy, the HER2 status may change in 5-30% of patients and re-biopsy of recurrent tumor may be difficult.
- Functional imaging with PET provides information about tumor biology and may predict for drug resistance.
- Normal tissues express HER2 and may uptake radiolabeled trastuzumab compromising PET image quality.

Hypothesis

64Cu-DOTA-Trastuzumab PET image quality can be improved by a pre-injection of cold trastuzumab.

Eligibility

1. Histological confirmation of metastatic invasive breast cancer outside of the region of the primary tumor and axilla.
2. At least 1 non-hepatic site of metastasis > 2 cm in mean diameter in addition to the site that was biopsied.
3. The HER2 positive by IHC and/or FISH.
4. No prior anti-HER therapy within 2 months.
5. Normal cardiac ejection fraction.

Staging workup

- 18F-FDG whole body CT/PET
- Bone Scan
- Cardiac Ejection Fraction

Imaging

Day 0: Injection of assigned cold dose (5 mg, 50 mg or 4mg/kg) trastuzumab
Injection of 15 mCi 64Cu-DOTA-Trastuzumab

Day 1: 64Cu-DOTA-Trastuzumab PET imaging

Day 2: 64Cu-DOTA-Trastuzumab PET imaging

Results in eight patients

Summary & Conclusions

- 64Cu-DOTA-Trastuzumab PET imaging is feasible.
- The pre-administration of 50 mg Trastuzumab improves image quality.
- Myocardial uptake of 64Cu-DOTA-Trastuzumab was not appreciated.

Phase II of the study will enroll women with advanced breast cancer that is 1+, and 2+ HER2 positive.

This study was funded by a Department of Defense grant, BC095002.
**Introduction**

HER2

- Human epidermal growth receptor 2 (HER2)
- Observed in 25-30% of breast cancers
- Associated with metastasis and decreased survival

**Trastuzumab (Herceptin®)**

- Monoclonal antibody
- Binds to HER2
- Used in conjunction with chemotherapy for treating HER2-positive breast cancer

**Radioabeled Trastuzumab**

- Radiolabeled with DOTA
- Used for imaging and therapy

**Preparation of 64Cu-DOTA-TRASTUZUMAB**

- Trastuzumab (Herceptin®, Genentech, Inc.)
- DOTA-trastuzumab and 18F-FDG
- GE Discovery STx 16 PET

**Results**

- **PET Imaging**
  - Use 64Cu-DOTA-trastuzumab for detecting and quantifying lesions in patients with HER2-positive metastatic breast cancer.
- **Statistical Analysis**
  - Linear regression analysis was used to compare the uptake of 64Cu-DOTA-trastuzumab to 18F-FDG.
  - Wilcoxon rank sum test was used to evaluate the effect of trastuzumab dose on organ uptake.

**Discussion**

- **Effect of Trastuzumab Protein Load on Tumor Uptake**
  - Uptake of 64Cu-DOTA-trastuzumab and 18F-FDG was uncorrelated within a given lesion, but there was a significant dependence on HER2 expression levels and tumor uptake of 64Cu-DOTA-trastuzumab.

**Conclusions**

- **PET Imaging**
  - 64Cu-DOTA-TRASTUZUMAB/PET-CT provides high tumor detection sensitivity in patients with HER2-positive disease.
- **PET Safety**
  - No adverse events related to the anti-trastuzumab antibody were observed.

**Methods**

- **PET Imaging**
  - GE Discovery STx 16 PET
  - Axial field of view 15.4 cm (47 slices)
  - Standard corrections for dead time, randoms, scatter, and attenuation (CT-based)

**Conclusion**

- **PET Imaging**
  - Detection sensitivity for nodes was lower for other sites.

**Hypothsis**

- 64Cu-DOTA-trastuzumab is sharply reduced at 50 vs 5 mg trastuzumab protein dose.